
Biofil Chemicals (BIOFILCHEM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
83.5M
Gross Profit
5.5M
6.55%
Operating Income
247.0K
0.30%
Net Income
2.0M
2.39%
Balance Sheet Metrics
Total Assets
509.6M
Total Liabilities
321.8M
Shareholders Equity
187.8M
Debt to Equity
1.71
Cash Flow Metrics
Revenue & Profitability Trend
Biofil Chemicals Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 334.0M | 400.4M | 300.4M | 223.8M | 357.5M |
Cost of Goods Sold | 313.1M | 375.1M | 274.2M | 194.6M | 324.3M |
Gross Profit | 20.9M | 25.3M | 26.1M | 29.2M | 33.2M |
Gross Margin % | 6.3% | 6.3% | 8.7% | 13.1% | 9.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 4.6M | 1.5M | 1.5M | 2.0M | 1.9M |
Other Operating Expenses | - | 8.9M | 6.7M | 5.8M | 6.3M |
Total Operating Expenses | 4.6M | 10.4M | 8.2M | 7.7M | 8.1M |
Operating Income | 4.7M | 4.2M | 7.4M | 9.0M | 11.9M |
Operating Margin % | 1.4% | 1.0% | 2.5% | 4.0% | 3.3% |
Non-Operating Items | |||||
Interest Income | - | 67.0K | 16.0K | 210.0K | 214.0K |
Interest Expense | 369.0K | 395.0K | 419.0K | 390.0K | 642.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 7.4M | 8.7M | 7.9M | 10.1M | 19.2M |
Income Tax | 1.8M | 1.6M | 2.3M | 3.2M | 6.8M |
Effective Tax Rate % | 24.2% | 18.0% | 29.3% | 31.2% | 35.3% |
Net Income | 5.6M | 7.1M | 5.6M | 7.0M | 12.4M |
Net Margin % | 1.7% | 1.8% | 1.9% | 3.1% | 3.5% |
Key Metrics | |||||
EBITDA | 11.5M | 13.0M | 12.6M | 14.9M | 21.2M |
EPS (Basic) | - | ₹0.44 | ₹0.34 | ₹0.44 | ₹0.77 |
EPS (Diluted) | - | ₹0.44 | ₹0.34 | ₹0.44 | ₹0.77 |
Basic Shares Outstanding | - | 16273800 | 16273800 | 16273800 | 16273800 |
Diluted Shares Outstanding | - | 16273800 | 16273800 | 16273800 | 16273800 |
Income Statement Trend
Biofil Chemicals Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.3M | 22.8M | 377.0K | 1.4M | 4.4M |
Short-term Investments | 1.2M | 21.9M | 117.0K | 600.0K | 4.3M |
Accounts Receivable | 383.2M | 330.3M | 205.0M | 71.7M | 172.2M |
Inventory | 33.4M | 25.5M | 12.1M | 12.9M | 43.4M |
Other Current Assets | 6.4M | 264.0K | 2.4M | 2.5M | 10.8M |
Total Current Assets | 425.5M | 384.1M | 223.5M | 93.1M | 234.6M |
Non-Current Assets | |||||
Property, Plant & Equipment | - | 2.4M | 2.4M | 2.4M | 2.4M |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 620.0K | -1.0K | -1.0K | -1.0K | - |
Total Non-Current Assets | 84.1M | 86.8M | 90.5M | 94.2M | 97.8M |
Total Assets | 509.6M | 470.8M | 314.1M | 187.3M | 332.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 309.9M | 275.5M | 126.5M | 6.0M | 158.5M |
Short-term Debt | 4.7M | 4.4M | 5.2M | 4.6M | 4.3M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 1.8M | 1.0K | -30.0K | -1.0K | - |
Total Current Liabilities | 318.5M | 285.2M | 137.3M | 14.9M | 167.5M |
Non-Current Liabilities | |||||
Long-term Debt | - | - | - | - | - |
Deferred Tax Liabilities | 3.3M | 3.6M | 3.8M | 4.0M | 3.6M |
Other Non-Current Liabilities | -1.0K | - | - | -1.0K | - |
Total Non-Current Liabilities | 3.3M | 3.6M | 3.8M | 4.0M | 3.6M |
Total Liabilities | 321.8M | 288.8M | 141.0M | 18.9M | 171.1M |
Equity | |||||
Common Stock | 162.7M | 162.7M | 162.7M | 162.7M | 162.7M |
Retained Earnings | - | -316.9M | -326.0M | -330.6M | -337.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 187.8M | 182.0M | 173.0M | 168.4M | 161.3M |
Key Metrics | |||||
Total Debt | 4.7M | 4.4M | 5.2M | 4.6M | 4.3M |
Working Capital | 107.1M | 98.8M | 86.3M | 78.2M | 67.1M |
Balance Sheet Composition
Biofil Chemicals Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 7.4M | 8.7M | 7.9M | 10.1M | 19.2M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -63.5M | -138.5M | -131.0M | 138.6M | 94.5M |
Operating Cash Flow | -55.8M | -129.5M | -122.7M | 149.1M | 114.4M |
Investing Activities | |||||
Capital Expenditures | -1.0M | -229.0K | -106.0K | -699.0K | -961.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -1.0M | -229.0K | -106.0K | -699.0K | -961.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | - | 82.6M | 576.0K | 348.0K | - |
Free Cash Flow | -20.2M | 23.7M | -1.2M | -2.9M | 5.4M |
Net Change in Cash | -56.8M | -47.1M | -122.2M | 148.8M | 113.4M |
Cash Flow Trend
Biofil Chemicals Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
128.47
Price to Book
3.87
Price to Sales
2.13
Profitability Ratios
Profit Margin
1.67%
Operating Margin
3.13%
Return on Equity
3.02%
Return on Assets
0.99%
Financial Health
Current Ratio
1.34
Debt to Equity
2.51
Beta
0.97
Per Share Data
EPS (TTM)
₹0.34
Book Value per Share
₹11.29
Revenue per Share
₹20.36
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
biofilchem | 710.8M | 128.47 | 3.87 | 3.02% | 1.67% | 2.51 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.42 | 10.88 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 45.5B | -13.34 | -21.04 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.4B | 23.59 | 3.25 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.9B | 154.18 | 6.24 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.